Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Etropal ADXBUL:ETR 51 EPS without NRI is €0.07 as of Dec. 2025. GuruFocus rates XBUL:ETR with a GF Score™ of 51/100 and a GF Value™ of €8.70 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 659 Medical Devices & Instruments companies, Etropal AD ranks worse than 151744.92% on this metric.
Etropal AD's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €0.07.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €0.07.
During the past 12 months, Etropal AD's average earnings per share (NRI) Growth Rate was 126.70% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Etropal AD's EPS without NRI or its related term are showing as below:
During the past 13 years, Etropal AD's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 100.00% per year. The lowest was 46.50% per year. And the median was 61.80% per year.
XBUL:ETR's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.1 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Etropal AD's EPS (Diluted) for the
six
months ended in Dec. 2025 was €0.03.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.03.
Etropal AD's EPS (Basic) for the
six
months ended in Dec. 2025 was €0.03.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.03.
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Etropal AD EPS without NRI Related Terms
Etropal AD EPS without NRI Historical Data
* Premium members only.
The historical data trend for Etropal AD's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Etropal AD's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a EPS without NRI of €0.07 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #999999 out of 659 companies in the Medical Devices & Instruments industry.
Is Etropal AD's EPS without NRI too high?
Etropal AD's current EPS without NRI is €0.07. Based on the distribution chart, Etropal AD ranks #999999 out of 659 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Etropal AD has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #999999 out of 659 companies for EPS without NRI. This places Etropal AD in the lower half of its industry. The industry median EPS without NRI is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current EPS without NRI is €0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.70, compared to a current price of €2.66 — trading 69.4% below its estimated fair value. The current EPS without NRI is €0.07. Etropal AD's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current EPS without NRI is €0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.66 is trading 69.4% below its estimated GF Value™ of €8.70.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
EPS without NRI: €0.07
GF Value™: €8.70 vs. price of €2.66 (69.4% below fair value)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
51GF Score
Get the complete analysis for XBUL:ETR
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
